Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Foghorn Therapeutics (FHTX)
NASDAQ:FHTX
Holding FHTX?
Track your performance easily
FHTX Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$2.70 - $10.25
Previous Close$5.51
Volume196.76K
Average Volume (3M)158.84K
Market Cap
$306.32M
Enterprise Value$77.99M
Total Cash (Recent Filing)$267.40M
Total Debt (Recent Filing)$39.07M
Price to Earnings (P/E)―
Beta3.21
Next Earnings
Mar 06, 2025EPS Estimate
-$0.31Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.91
Shares Outstanding55,593,131
10 Day Avg. Volume227,402
30 Day Avg. Volume158,839
Standard Deviation0.34
R-Squared0.19
Alpha-0.01
Financial Highlights & Ratios
Price to Book (P/B)-10.80
Price to Sales (P/S)11.55
Price to Cash Flow (P/CF)-3.50
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue3.06
Enterprise Value/Gross Profit2.28
Enterprise Value/Ebitda-0.89
Forecast
1Y Price Target
$10.33Price Target Upside87.48% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
Foghorn Therapeutics News
PremiumCompany Announcements
Foghorn Therapeutics Advances Precision Oncology Pipeline
PremiumCompany Announcements
Foghorn Therapeutics Reports Third Quarter Highlights
PremiumCompany Announcements
Foghorn Therapeutics Advances Oncology Pipeline with New TrialsBulls Say, Bears Say
Bulls Say
Clinical DevelopmentThe first patient was dosed in a Ph1 trial of FHD-909 in SMARCA4-mutated cancers, with NSCLC as the target patient population.
Market PotentialFHD-909 targets a substantial market of about 5% of all solid tumors and up to 10% of NSCLC, with NSCLC as the primary focus.
Pipeline StrategyThe decision to discontinue efforts with FHD-286 strengthens the company's focus on FHD-909, along with earlier-stage pipeline programs including Foghorn's CBP, EP300, and ARID1B degraders.
Bears Say
Drug DevelopmentFoghorn announced that the company will no longer pursue independent development for SMARCA2/SMARCA4 inhibitor FHD-286 in relapsed/refractory acute myeloid leukemia following a review of a data cut for FHD-286 + decitabine in this patient population.
Financial PerformanceFoghorn reported Q3 collaboration revenue of $7.8M below our $10M estimate.
Stock PressureShares are expected to face pressure given the uncertainty posed by the FHD-286 halt and the lack of significant near-term catalysts.
---
Ownership Overview
1.42% Insiders
11.40% Mutual Funds
44.68% Other Institutional Investors
37.60% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
FHTX FAQ
What was Foghorn Therapeutics’s price range in the past 12 months?
Foghorn Therapeutics lowest stock price was $2.70 and its highest was $10.25 in the past 12 months.
What is Foghorn Therapeutics’s market cap?
Currently, no data Available
When is Foghorn Therapeutics’s upcoming earnings report date?
Foghorn Therapeutics’s upcoming earnings report date is Mar 06, 2025 which is in 78 days.
How were Foghorn Therapeutics’s earnings last quarter?
Foghorn Therapeutics released its earnings results on Nov 04, 2024. The company reported -$0.31 earnings per share for the quarter, beating the consensus estimate of -$0.43 by $0.12.
Is Foghorn Therapeutics overvalued?
According to Wall Street analysts Foghorn Therapeutics’s price is currently Undervalued.
Does Foghorn Therapeutics pay dividends?
Foghorn Therapeutics does not currently pay dividends.
What is Foghorn Therapeutics’s EPS estimate?
Foghorn Therapeutics’s EPS estimate is -$0.31.
How many shares outstanding does Foghorn Therapeutics have?
Foghorn Therapeutics has 55,593,132 shares outstanding.
What happened to Foghorn Therapeutics’s price movement after its last earnings report?
Foghorn Therapeutics reported an EPS of -$0.31 in its last earnings report, beating expectations of -$0.43. Following the earnings report the stock price went up 8.495%.
Which hedge fund is a major shareholder of Foghorn Therapeutics?
Among the largest hedge funds holding Foghorn Therapeutics’s share is Flagship Pioneering Inc.. It holds Foghorn Therapeutics’s shares valued at 118M.
---
Foghorn Therapeutics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$10.33 (87.48% Upside)
$10.33 (87.48% Upside)
Hedge Fund Trend
Decreased
By 603.1K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.7%
Last 30 Days ▼ 14.9%
Last 30 Days ▼ 14.9%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
4.15%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-1.61%
Trailing 12-Months
Company Description
Foghorn Therapeutics
Foghorn Therapeutics Inc is engaged in discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system, an untapped opportunity for therapeutic intervention. Its proprietary Gene Traffic Control platform gives us an integrated, mechanistic understanding of how the various components of the chromatin regulatory system interact, allowing it to identify, validate and potentially drug targets within the system. The company is developing FHD-286, a selective, allosteric ATPase inhibitor, and FHD-609, a protein degrader, to treat hematologic cancers and solid tumors.
---
FHTX Stock 12 Month Forecast
Average Price Target
$10.33
▲(87.48% Upside)
Technical Analysis
Best Analysts Covering FHTX
1 Year
1 Year Success Rate
3/10 ratings generated profit
1 Year Average Return
-18.34%
reiterated a buy rating 4 months ago
Copying Robert Driscoll's trades and holding each position for 1 Year would result in 30.00% of your transactions generating a profit, with an average return of -18.34% per trade.
---